Alessandro Vinciguerra1,2, Andrea Rampi1,2, Mona-Rita Yacoub3, Moreno Tresoldi4, Umberto Tanzini1,2, Mario Bussi1,2, Matteo Trimarchi5,6. 1. Otorhinolaryngology Unit, Division of Head and Neck Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. 2. Division of Otolaryngology, Department of Surgical Sciences, IRCCS San Raffaele Hospital, School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 68, 20100, Milan, Italy. 3. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. 4. General Medicine and Advanced Care Unit, All at IRCCS San Raffaele Scientific Institute, Milan, Italy. 5. Otorhinolaryngology Unit, Division of Head and Neck Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. trimarchi.matteo@hsr.it. 6. Division of Otolaryngology, Department of Surgical Sciences, IRCCS San Raffaele Hospital, School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 68, 20100, Milan, Italy. trimarchi.matteo@hsr.it.
Abstract
PURPOSE: Biological therapies are gaining relevance in the management of CRSwNP with few adverse events reported. Among these, dupilumab, an anti-IL4-Ra monoclonal antibody, is frequently associated with hypereosinophilia (HE) which usually remains silent and progressively resolves, although some cases of systemic involvement occurs. The aim of this paper is to describe our experience and propose a management flowchart for HE during therapy with dupilumab. METHODS: Patients with CRSwNP who satisfied EPOS2020 criteria for biological therapies were included in this prospective study. Each case was discussed in a multidisciplinary meeting with subsequent prescription of dupilumab; all patients were candidates to follow-up bi-monthly for 6 months, while additional blood tests were scheduled in the event of HE. RESULTS: A total of 21 patients with a mean age of 48.4 years were enrolled. Of these, 15 of 21 presented an asthma comorbidity and 9 of 21 ASA sensitivity. Four patients (19%) developed HE with AEC > 1.5 × 109/L, whereas it occurred in 9.5% (two patients) if considered AEC > 3 × 109/L. No cases of hypereosinophilic syndrome were recorded. Following our decision-making flowchart, two patients received short-term corticosteroid therapy, whereas the other two were only eligible for closer follow-up. CONCLUSIONS: During dupilumab therapy, HE may occur and should be considered benign when < 3 × 109/L in the absence of organ involvement. Conversely, in case of HE ≥ 3 × 109/L, an empirical approach with short-term corticosteroid therapy should be considered to debulk the blood from eosinophils and prevent potential organ involvement.
PURPOSE: Biological therapies are gaining relevance in the management of CRSwNP with few adverse events reported. Among these, dupilumab, an anti-IL4-Ra monoclonal antibody, is frequently associated with hypereosinophilia (HE) which usually remains silent and progressively resolves, although some cases of systemic involvement occurs. The aim of this paper is to describe our experience and propose a management flowchart for HE during therapy with dupilumab. METHODS: Patients with CRSwNP who satisfied EPOS2020 criteria for biological therapies were included in this prospective study. Each case was discussed in a multidisciplinary meeting with subsequent prescription of dupilumab; all patients were candidates to follow-up bi-monthly for 6 months, while additional blood tests were scheduled in the event of HE. RESULTS: A total of 21 patients with a mean age of 48.4 years were enrolled. Of these, 15 of 21 presented an asthma comorbidity and 9 of 21 ASA sensitivity. Four patients (19%) developed HE with AEC > 1.5 × 109/L, whereas it occurred in 9.5% (two patients) if considered AEC > 3 × 109/L. No cases of hypereosinophilic syndrome were recorded. Following our decision-making flowchart, two patients received short-term corticosteroid therapy, whereas the other two were only eligible for closer follow-up. CONCLUSIONS: During dupilumab therapy, HE may occur and should be considered benign when < 3 × 109/L in the absence of organ involvement. Conversely, in case of HE ≥ 3 × 109/L, an empirical approach with short-term corticosteroid therapy should be considered to debulk the blood from eosinophils and prevent potential organ involvement.
Authors: Klaus F Rabe; Parameswaran Nair; Guy Brusselle; Jorge F Maspero; Mario Castro; Lawrence Sher; Hongjie Zhu; Jennifer D Hamilton; Brian N Swanson; Asif Khan; Jingdong Chao; Heribert Staudinger; Gianluca Pirozzi; Christian Antoni; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Neil M H Graham; Neil Stahl; George D Yancopoulos; Ariel Teper Journal: N Engl J Med Date: 2018-05-21 Impact factor: 91.245
Authors: Christen L Andersen; Volkert D Siersma; Hans C Hasselbalch; Hanne Vestergaard; Ruben Mesa; Peter Felding; Niels D F Olivarius; Ole W Bjerrum Journal: Am J Hematol Date: 2015-01-16 Impact factor: 10.047
Authors: Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent Journal: Lancet Date: 2019-09-19 Impact factor: 79.321
Authors: A Wollenberg; L A Beck; A Blauvelt; E L Simpson; Z Chen; Q Chen; B Shumel; F A Khokhar; T Hultsch; E Rizova; A B Rossi; N M H Graham; G Pirozzi; Y Lu; M Ardeleanu Journal: Br J Dermatol Date: 2019-12-01 Impact factor: 9.302
Authors: William W Busse; Jorge F Maspero; Klaus F Rabe; Alberto Papi; Sally E Wenzel; Linda B Ford; Ian D Pavord; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Bolanle Akinlade; Laurent Eckert; Jingdong Chao; Neil M H Graham; Ariel Teper Journal: Adv Ther Date: 2018-05-03 Impact factor: 3.845